Teva Pharmaceutical Industries (TEVA) EBT Margin (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly EBT Margin came in at 10.99% in Q2 2026, down 1585.0% on a YoY basis from 0.74% in Q2 2025, and down 200.1% quarter-over-quarter from 10.97% in Q1 2026.
Powered by 
Analysis
Teva Pharmaceutical Industries (TEVA) EBT Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported EBT Margin for 18 consecutive years, with 10.99% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 1585.0% year-over-year to 10.99%; the trailing twelve-month figure through Jun 2026 stood at 4.09% (up 457.0% YoY), and the FY2025 full-year result was 7.09%, up 1485.0% from the prior year.
- EBT Margin eased to 10.99% in Q2 2026 per TEVA's latest filing, from 10.97% in the prior quarter.
- Across five years, EBT Margin topped out at 14.42% in Q3 2025 and bottomed at 31.11% in Q2 2022.
- Historically, EBT Margin has averaged 4.6% across 5 years, with a median of 2.12% in 2023.
- The sharpest annual moves came in 2022 and 2023: EBT Margin plunged 3899 bps in 2022, then soared 4189 bps in 2023.
- Over 5 years, EBT Margin stood at 30.51% in 2022, then jumped by 137 bps to 11.38% in 2023, then plunged by 175 bps to 8.52% in 2024, then jumped by 120 bps to 1.7% in 2025, then plunged by 747 bps to 10.99% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 10.99%, 10.97%, and 1.7% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.60 Bn | 38.95 Bn | 2.15 Bn | -10.99% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -1.70% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 6.85% |
| 4 | Amneal Pharmaceuticals | 5.46 Bn | 5.33 Bn | 334.51 Mn | 8.92% |
| 5 | Bausch Health Companies | 2.36 Bn | 520.75 Mn | 2.10 Bn | 12.20% |
| 6 | Alvotech | 1.51 Bn | 1.37 Bn | 2.56 Mn | -121.92% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 13.94% |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 20.96% |
| 9 | Fennec Pharmaceuticals | 411.09 Mn | 369.84 Mn | 17.15 Mn | 11.27% |
| 10 | RedHill Biopharma | 181.39 Mn | 181.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.99% |
| Mar 31, 2026 | 10.97% |
| Dec 31, 2025 | 1.70% |
| Sep 30, 2025 | 14.42% |
| Jun 30, 2025 | 4.86% |
| Mar 31, 2025 | 7.56% |
| Dec 31, 2024 | -8.52% |
| Sep 30, 2024 | -7.48% |
| Jun 30, 2024 | -5.91% |
| Mar 31, 2024 | 12.23% |
| Dec 31, 2023 | 11.38% |
| Sep 30, 2023 | 1.66% |
| Jun 30, 2023 | -23.80% |
| Mar 31, 2023 | -7.43% |
| Dec 31, 2022 | -30.51% |
| Sep 30, 2022 | 4.76% |
| Jun 30, 2022 | -31.11% |
| Mar 31, 2022 | -26.52% |
| Dec 31, 2021 | -4.27% |
| Sep 30, 2021 | 9.83% |